Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353
Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.
Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled trial. After Week 48, patients could enter a 104-week open-label extension, receiving bimekizumab 160 mg every four weeks. Patient reported outcome measures assessed included VAS, PsAID, and SF-36 amongst others.
These findings highlight a real long-term benefit to the use of Bimekizumab. Such long-term improvements could help to improve the treatment landscape for patients with PsA.